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CLINICAL INQUIRIES
What is the best surveillance 
for hepatocellular carcinoma 
in chronic carriers of hepatitis B?
■ Evidence summary
Many serum markers and screening meth-
ods have been proposed to detect hepato-
cellular carcinoma at a treatable stage, but
only 2—AFP and US—are in clinical use.1
A Cochrane systematic review on
screening for hepatocellular carcinoma in
the HBsAg+ population was published in
2003 and updated May 2004.2 Our litera-
ture search did not find any subsequent rel-
evant trials. The Cochrane review included
2 randomized control trials. The larger
trial was performed in Shanghai, China
and included 18,816 HBsAg+ patients
aged 35 to 55 years.3 Subjects were recruit-
ed from their place of employment and
randomized to either AFP/US every 6
months (n=9373) or to no screening
(n=9443). 
Fifty-one hepatocellular carcinomas
were diagnosed in the control group and
86 in screened group. Screened subjects
had a significantly higher percentage of
tumors that were less than 5 cm at the time
of diagnosis and a higher number of
patients who underwent resection. While
Screening patients with chronic hepatitis B infec-
tion (HBsAg+) for hepatocellular carcinoma by
alpha-fetoprotein (AFP) or by AFP plus ultrasound
(AFP/US) detects hepatocellular carcinoma tumors
at earlier stages and increases resection rates
(strength of recommendation [SOR]: B, based 
on a systematic review of fair-quality randomized
controlled trials). It is unclear whether screening
with AFP or AFP/US improves disease-specific or
all-cause mortality (SOR: B). 
E V I D E N C E - B A S E D A N S W E R
Offer screening to all with chronic hepatitis B
infection, but stratify risk for HCC first 
Because no mortality benefit to screening for 
hepatocellular carcinoma has been shown, we
should give added consideration to how we 
counsel our patients before offering screening,
particularly since positive screening results can
lead to further invasive studies. An important 
consideration for me is whether a patient has, or is
at risk, for cirrhosis, because the incidence of 
hepatocellular carcinoma is higher if cirrhosis is
present. Screening for coinfection with hepatitis C
or a history of alcohol abuse becomes especially
critical in this situation. Biochemical evidence of
chronic active liver inflammation, whatever the
cause, should also be an important factor in 
deciding whether to screen. While I still offer
screening to all patients with chronic hepatitis B
infection, it helps to have stratified a patient’s
underlying risk for hepatocellular carcinoma first
and counseling him or her accordingly.
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ies were present at the start of the studies
and did not represent newly incident
tumors detected by regular screening.3,5
Both of these trials would be improved
if they started with cohorts known to be
disease-free at baseline. Additionally, the
Shanghai study randomized patients in
clusters. The only English-language report
of this study did not describe whether
adjustments for this were made in analy-
sis;5 failing to do so could overestimate the
benefit of screening.
Recommendations from others
The American Association for the Study
of Liver Disease recommends that carri-
ers of the hepatitis B virus who are at
high risk for developing hepatocellular
carcinoma—men aged >45 years, those
with cirrhosis or a family history of hepa-
tocellular carcinoma—should be
screened periodically with AFP/US. Also
consider periodic screening for low-risk
HBsAg+ patients who are from an area
where hepatocellular carcinoma is
endemic (SOR: C, based on expert opin-
ion or descriptive epidemiology).6
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the 5-year survival for those with hepato-
cellular carcinoma in the screened group
was higher, the disease-specific mortality
rate was not statistically different between
the 2 groups. 
Additional data became available in
2002. The original study authors claimed
the new data showed a statistically signifi-
cant disease-specific mortality rate ratio of
0.63, favoring the screened group.4
However, the Cochrane group performed
their own analysis on the same data and
determined that no statistically significant
difference in the disease-specific mortality
rates existed between the 2 groups.2
Therefore, it is not clear whether these new
data definitively demonstrate that screen-
ing provides any benefit.
The other randomized control trial
took place in Toronto, and included 1069
patients, 71% of whom were of Asian
ancestry. Subjects had AFP testing every 6
months, and half were randomly assigned
to have US performed every 6 months.5
Eight of the 11 incident tumors would
have been diagnosed based on AFP levels
alone, and 3 would have been missed with
US alone. The authors conclude that for
AFP, sensitivity=64.3% and specifici-
ty=91.4%; for US, sensitivity=78.8% and
specificity=93.8%. However, their study
was too small to determine if AFP/US is
superior to AFP for hepatocellular carcino-
ma screening in a HBsAg+ population.
They estimate that detecting such a differ-
ence would take a sample size of 10,000 or
more.
Both studies have important flaws.
Neither study applied a reference standard
test (such as a computed tomography scan
or magnetic resonance imaging) to both
study arms. Carcinomas may have been
undetected by either AFP or US.  Without
knowing the real prevalence of hepatocel-
lular carcinoma, the true sensitivity and
specificity for AFP, US, and AFP/US in
these studies cannot be determined. Both
studies included prevalent tumors (tumors
diagnosed during the very first screening
cycle) in their analysis. Approximately
20% of detected carcinomas in both stud-
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